The use of in vitro metabolic parameters and physiologically based pharmacokinetic (PBPK) modeling to explore the risk assessment of trichloroethylene

Environmental Toxicology and Pharmacology

Volumn 11, Issue 3-4, 2002, Pages 259-271

  Hissink, Erna M ^a   Bogaards, Jan J P ^a   Freidig, Andreas P ^a   Commandeur, Jan N M ^b   Vermeulen, Nico P E ^b   Van Bladeren, Peter J ^a,c  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c NESTLÉ RESEARCH CENTER   (Switzerland)

Author keywords

PBPK; Radioactivity; Trichloroethylene

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; GLUTATHIONE TRANSFERASE; TRICHLOROETHYLENE;

AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME KINETICS; EXPOSURE; IN VITRO STUDY; MALE; METABOLISM; MODEL; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY; RAT; RISK ASSESSMENT; VALIDATION PROCESS;

RATTUS NORVEGICUS;

EID: 0036290174     PISSN: 13826689     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1382-6689(02)00019-4     Document Type: Article

References (49)

1. A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol glucuronide in B6C3F1 mice
2. Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform
3. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride
4. An improved method for the separation and quantification of glutathione S-transferase subunits in rat tissue using high-performance liquid chromatography
5. Conjugation of isoprene monepoxides with glutathione, catalyzed by α, μ, π and θ-class glutathione S-transferases of rat and man
6. Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically-based pharmacokinetic modeling
7. Health risk assessment of environmental exposure to trichloroethylene
8. Physiological parameter values for physiologically based pharmacokinetic models
9. Mode of action of liver tumor induction by trichloroethylene and its metabolites, trichloroacetic acid and dichloroacetic acid
10. The application of physiologically based pharmacokinetic modeling in human health risk assessment of hazardous substances
11. Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk
12. Development of a physiologically-based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment
13. Identification of N-acetyl(2,2-dichlorovinyl)- and N-acetyl(1,2-dichlorovinyl)-L-cysteine as two regioisomeric mercapturic acids of trichloroethylene in the rat
14. Enzymes and transport systems involved in the formation and disposition of glutathione S-conjugates. Role in bioactivation and detoxication mechanisms of xenobiotics
15. Glutathione S-transferase distribution and concentration in human organs
16. A trichloroethylene risk assessment using a Monte Carlo analysis of parameter uncertainty in conjunction with physiologically-based pharmacokinetic modeling
17. Role of cytochrome P450 and glutathione S-transferase alpha in the metabolism and cytotoxicity of trichloroethylene in the rat
18. Consideration of the target organ toxicity of trichloroethylene in terms of metabolite toxicity and pharmacokinetics
19. Metabolism of trichloroethylene. In vivo and in vitro; Evidence for activation by glutathione conjugation
20. Identification of S-(1,2-dichlorovinyl) glutathione-induced nephrotoxicity
21. Exploration of an interaction treshold for the joint toxicity of trichloroethylene and 1.1-dichloroethene utilization of a PBPN Model
22. A human physiologically based pharmacokinetic model for trichloroethylene and its metabolites, trichloroacetic acid and free trichloroethanol
23. P450 2E1 expression in liver, kidney, and lung of rats treated with single or combined inducers
24. Metabolism and kinetics of trichloroethylene in relation to toxicity and carcinogenicity. Relevance of the mercapturic acid pathway
25. Formic acid excretion in rats exposed to trichloroethylene: A possible explanation for renal toxicity in long-term studies
26. Pulmonary toxicity and carcinogenicity of trichloroethylene, species differences and mode of action
27. Physiologically based pharmacokinetic modeling of inhaled trichloroethylene and its oxidative metabolites in B6C3F1 mice
28. Role of human cytochrome P450IIE1 in the oxidation of many low molecular weight cancer suspects
29. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples
30. Conjugation of carcinogens by theta class glutathione s-transferases: Mechanisms and relevance to variations in human risk
31. Human interindividual variability in susceptibility to toxic effects: From annoying detail to a central determinant of risk
32. In vivo disposition of caffeine predicted from hepatic microsomal and hepatocyte data
33. A physiologically based pharmacokinetic (PB-PK) model for ethylene dibromide; Relevance of extrahepatic metabolism
34. Predicting the hepatic clearance of xenobiotics in humans from in vitro data
35. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance
36. Kinetic analysis of furan biotransformation by F-344 rats in vivo and in vitro
37. Metabolsim of trichloroethylene
38. An assessment of the carcinogenic potential of trichloroethylene in humans
39. Cytochrome P450-dependent metabolism of trichloroethylene: Interindividual differences in humans
40. Role of cytochrome P4502E1 in alcohol liver disease pathogenesis
41. Metabolism of trichloroethylene in man. II. Pharmacokinetics of metabolites
42. The use of human in vitro metabolic parameters to explore the risk assessment of hazardous compounds: The case of ethylene dibromide
43. Species differences in response to trichloroethylene. I. Pharmacokinetics in rats and mice
44. Evidence that human class theta glutathione S-transferase T1-1 can catalyse the activation of dichloromethane, a liver and lung carcinogen in the mouse. Comparison of the tissue distribution of GSTT1-1 with that of class Alpha, Mu, and Pi GST in human
45. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, Carcinogens and toxic chemicals: Studies with human liver microsomes of 30 Japanese and 30 Caucasians
46. Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal livers and adult lungs
47. Quantification of human hepatic glutathione S-transferases
48. Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione S-transferase and epoxide hydrolase enzymes